drugset
Drugs / zigakibart
last change Jun 2026 re-read 2 minutes ago

zigakibart

also known as BION-1301 · C-90401

Monoclonal antibody

Developed for
IgA glomerulonephritis · plasma cell myeloma
Investigated by
Novartis Pharmaceuticals · Chinook Therapeutics, Inc.

Trials 7 · a red edge is where a trial was stopped

today NCT07146906 · Ph 2 NCT06858319 · Ph 3 NCT05852938 · Ph 3 NCT05508204 · Ph 1 NCT04573478 · Ph 3 NCT03945318 · Ph 1/2 NCT03340883 · Ph 1/2
20182019202020212022202320242025202620272028202920302031
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT05508204 Jul → Dec 2022 — Chinook Therapeutics, Inc. Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT03945318 Apr 2019 → Jun 2026 IgA glomerulonephritis Novartis Pharmaceuticals Completed No outcome recorded
Phase 1/2 NCT03340883 Nov 2017 → Jun 2019 plasma cell myeloma Chinook Therapeutics, Inc. Terminated No outcome recorded
Phase 21 trial
Phase 2 NCT07146906 Mar 2026 → Jul 2030 expected IgA glomerulonephritis Novartis Pharmaceuticals Recruiting No outcome recorded
Phase 33 trials
Phase 3 NCT06858319 Jul 2025 → Jun 2031 expected IgA glomerulonephritis, chronic kidney disease Novartis Pharmaceuticals Recruiting No outcome recorded
Phase 3 NCT05852938 Jul 2023 → Aug 2027 expected IgA glomerulonephritis Novartis Pharmaceuticals Active not recruiting No outcome recorded
Phase 3 NCT04573478 Dec 2020 → Apr 2028 expected IgA glomerulonephritis Novartis Pharmaceuticals Active not recruiting No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as zigakibart ClinicalTrials.gov intervention name — accepted as the source's own label NCT06858319 ↗
2

NCT04573478 ↗

NCT07146906 ↗
Known as BION-1301 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05852938 ↗
3

NCT05508204 ↗

NCT03945318 ↗

NCT03340883 ↗
Known as C-90401 ChEMBL registry synonym — accepted as the source's own label CHEMBL5095316 ↗
Action Inhibit “durable reductions in levels of free APRIL” PMID 40482854 ↗ Jun 2025
Modality Monoclonal antibody “a humanized monoclonal antibody” NCT03340883 ↗
Route Intravenous “administered by intravenous (IV) infusion” NCT03945318 ↗